Research Article
Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients
Table 2
Progression-free survival rate age at 3 and at 6 months, the mean and median number of treatment cycles received, the parametric description of survival with the lognormal distribution, and average survival times. The estimated average survival time with the lognormal distribution is calculated by exp (μ + σ2/2).
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PFS: progression-free survival; OS: overall survival. |